buy heme/onc pipelin updat
forward-i trial maintain buy
messag report financi result today gener in-lin
expect phase forward-i track report top-lin data new cohort
ad forward-ii combin studi visibl
develop potenti two earli stage heme/onc asset upcom meet
reiter buy rate
report financi result today gener in-lin expect
oper expens slightli consensu
cash cash equival end updat cash revenu
guidanc expect cash year-end updat
estim reflect financi result
phase forward-i track report top-lin data recal forward-i
enrol platinum-resist ovarian cancer proc patient follow prior line
therapi random receiv either mirvetuximab singl agent physician
choic singl agent chemotherapi trial hierarch test design
succeed either intent treat patient popul subset folate-
receptor fr -high patient remain posit bias success probabl
forward-i base analysi histor dataset check ovarian
cancer kol see note
new cohort ad forward-ii combin studi multi-
arm phase i/ii forward-ii studi combin mirvetuximab sever approv agent
goal potenti expand commerci opportun mirvetuximab ovarian
cancer result avastin keytruda combin cohort
previous report esmo annual meet respect indic
increas respons durat singl agent data third expans cohort
combin mirvetuximab avastin carboplatin platinum-sensit ovarian cancer
psor patient current enrol top-lin data expect addit
management note today call new cohort combin mirvetuximab avastin
recurr ovarian cancer patient irrespect platinum sensit plan start
visibl develop potenti two earli stage heme/onc asset
upcom meet investigatro present two oral present
target target two
phase dose-escal partner see note believ
limit valu current reflect share agent
reiter buy rate follow recent stock pull-back think
risk/reward own skew upsid buy thesi primarili
support three argument believ lead candid mirvetuximab higher
po platinum-resist ovarian cancer proc current account stock
market opportun proc significantli larger anticip investor
us alon estim potenti penetr psoc market repres
addit upsid valu current stock earli clinic stage asset
partner address valid target hem cancer
sourc signific upsid potenti view
page analyst certif import disclosur
valuat risk
valu per share use dcf base valuat method valuat
includ lead product candid mirvetuximab well probability-adjust cash flow deriv
compani pipelin use discount rate consist commerci
stage biotech compani coverag termin growth rate appli
termin year post-assum mirvetuximab biosimilar entri
risk valuat includ regulatori commerci setback potenti
emerg new competitor /or lower product sale expect risk
intellectu properti risk manag execut misstep
page analyst certif import disclosur
licens mileston fee
total cost expens
total expens incom
guggenheim secur llc estim sec file
page analyst certif import disclosur
licens mileston fee
total expens incom
net incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
